Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026)

Regeneron Pharmaceuticals has reported Non-cash Items for 18 years, with the latest figure at $351.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items rose 48.77% year-over-year to $351.7 million; the trailing twelve-month figure through Mar 2026 stood at $589.3 million (up 207.89% YoY), and the FY2025 full-year result was $474.0 million, up 5900.0% from the prior year.
• Non-cash Items for Q1 2026 stood at $351.7 million, up from $326.1 million in the prior quarter.
• The five-year high for Non-cash Items was $1.1 billion in Q1 2022, with the low at -$1.1 billion in Q2 2024.
• Average Non-cash Items over 5 years is $126.5 million, with a median of $158.7 million recorded in 2025.
• Peak annual rise in Non-cash Items reached 593.71% in 2024, while the deepest fall reached 2096.85% in 2024.
• Tracing REGN's Non-cash Items over 5 years: stood at $522.8 million in 2022, then tumbled by 113.37% to -$69.9 million in 2023, then soared by 593.71% to $345.1 million in 2024, then slipped by 5.51% to $326.1 million in 2025, then climbed by 7.85% to $351.7 million in 2026.
• The last three Non-cash Items figures came in at $351.7 million (Q1 2026), $326.1 million (Q4 2025), and $158.7 million (Q3 2025), per Business Quant data.

Peer Comparison